Sarlis Nicholas J. 4
4 · SELLAS Life Sciences Group, Inc. · Filed Mar 15, 2018
Insider Transaction Report
Form 4
Sarlis Nicholas J.
Chief Medical Officer and SVP
Transactions
- Award
Stock Option (Right to Buy)
2018-03-13+70,000→ 70,000 totalExercise: $5.24Exp: 2028-03-12→ Common Stock (70,000 underlying)
Footnotes (1)
- [F1]One-quarter (1/4) of the option shares will vest and became exercisable one year from the March 13, 2018 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date.